Rocuronium

Generic Name: Rocuronium

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₅₃N_₂O_₄

CAS Number: 143558-00-3

Unique Ingredient Identifier: WRE554RFEZ

Background: Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, ro...

Indication: For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Associated Conditions: Muscle fasciculation caused by succinylcholine

Associated Therapies: Curarization therapy, Neuromuscular blocking therapy, Facilitation of small bowel intubation therapy

Clinical Trials

Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)

Completed

Conditions: Anesthesia

Interventions: Drug: Rocuronium

First Posted Date: 2009-05-14

Last Posted Date: 2015-10-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 3969

Registration Number: NCT00902070

Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

Phase 3

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: succinylcholine
Drug: rocuronium
Drug: sugammadex

First Posted Date: 2008-09-11

Last Posted Date: 2015-06-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 161

Registration Number: NCT00751179

Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)

Phase 3

Completed

Conditions: Anesthesia, General

Interventions: Drug: Rocuronium
Drug: Sugammadex
Drug: Neostigmine
Drug: Atropine

First Posted Date: 2008-07-30

Last Posted Date: 2017-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 140

Registration Number: NCT00724932

Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)

Phase 3

Completed

Conditions: Anesthesia

Interventions: Drug: Sugammadex
Drug: Neostigmine
Drug: Rocuronium

First Posted Date: 2008-05-12

Last Posted Date: 2015-03-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 100

Registration Number: NCT00675792

Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Phase 3

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: sugammadex
Drug: Rocuronium

First Posted Date: 2008-04-11

Last Posted Date: 2015-03-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 6

Registration Number: NCT00656799

Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)

Phase 3

Completed

Conditions: Anesthesia, General

Interventions: Drug: Sugammadex
Drug: Rocuronium
Drug: Sevoflurane
Drug: Propofol

First Posted Date: 2007-11-16

Last Posted Date: 2019-11-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 52

Registration Number: NCT00559468

A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)

Phase 2

Completed

Conditions: Anesthesia, General

Interventions: Drug: Placebo
Drug: Sugammadex
Drug: Vecuronium
Drug: Rocuronium

First Posted Date: 2007-11-02

Last Posted Date: 2019-11-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 100

Registration Number: NCT00552617

Pharmacodynamic Trial on Rocuronium in Obese Patients

Phase 4

Completed

Conditions: Bariatric Surgery

Interventions: Drug: Rocuronium

First Posted Date: 2007-10-05

Last Posted Date: 2009-10-16

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 51

Registration Number: NCT00540085

Locations: 🇩🇰
Department of anaesthesia, Privathospitalet Hamlet A/S, Copenhagen, Denmark

Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)

Phase 3

Completed

Conditions: Anesthesia, General

Interventions: Drug: Sugammadex
Drug: Rocuronium

First Posted Date: 2007-05-21

Last Posted Date: 2019-04-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 86

Registration Number: NCT00475215

Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

Phase 3

Completed

Conditions: Anesthesia, General

Interventions: Drug: Sugammadex
Drug: Succinylcholine
Drug: Rocuronium

First Posted Date: 2007-05-16

Last Posted Date: 2019-04-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 115

Registration Number: NCT00474253

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy